Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Cancer Management and Research|April 13, 2016
Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancerEric S Schaefer, Christina Baik
Trends in Cancer|June 17, 2020
Clinical Development of BRAF plus MEK Inhibitor CombinationsVivek Subbiah, Christina Baik, John M Kirkwood
The Lancet. Oncology|September 5, 2014
Combination of stereotactic ablative body radiation with targeted therapiesJing Zeng, Christina Baik, Shailender Bhatia, et al.
Advances in Therapy|May 2, 2024
A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerChristina Baik, Michael L Cheng, Martin Dietrich, et al.
Clinical Lung Cancer|May 24, 2022
Systemic Treatment Patterns and Outcomes in Patients With EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal DiseaseCristina M Merkhofer, Boryana Eastman, Isabella Densmore, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 10, 2022
A qualitative study of interactions with oncologists among patients with advanced lung cancerMorhaf Al Achkar, Upal Basu Roy, Eugene Manley, et al.
Head & Neck|December 29, 2017
Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignanciesCristina P Rodriguez, Renato G Martins, Christina Baik, et al.
Cancer Treatment and Research Communications|June 12, 2021
A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapyChristina Baik, Sylvia Lee, Kitty Cook, et al.
Cancer Immunology Research|May 3, 2019
Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver MutationsJoshua R Veatch, Brenda L Jesernig, Julia Kargl, et al.
JCO Precision Oncology|June 18, 2026
Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2-Mutant Non-Small Cell Lung CancerChristine M Lovly, Christina Baik, Misako Nagasaka, et al.
Pageof 4